Novo Nordisk shares rose 2.7% on November 1, driven by a sector-wide rally following Eli Lilly's upgraded full-year sales guidance. However, the article clarifies that this stock movement reflects competitor momentum rather than Novo Nordisk's specific performance, as the Danish drugmaker prepares to release its own nine-month results on November 4. The company faces two distinct challenges ahead: a legal dispute over advertising claims and upcoming scientific presentations. A US judge rejected Novo Nordisk's request to halt Eli Lilly's weight-loss drug advertising, leaving the underlying marketing dispute unresolved. Simultaneously, Novo Nordisk plans to present clinical data on its pipeline compounds at major medical conferences in Denver and Atlanta later in November. Key attention is focused on post-hoc analyses of the REDEFINE 1 study presented on October 20, which showed CagriSema associated with an average 25.0% weight loss in women after 68 weeks. The article notes these findings are retrospective and assume adherence, serving as a preliminary clinical anchor rather than a substitute for the upcoming financial report or future data releases. Investors must distinguish between the external tailwind provided by Lilly's success and Novo Nordisk's internal trajectory. While the obesity market sentiment remains buoyant, the company's own commercial results published on November 4 will serve as the primary yardstick to determine its standing against competitors and validate recent market optimism.